9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation



Pembrolizumab in Treating Patients With Malignant Mesothelioma

Estimated reading time: < 1 min


Biphasic Mesothelioma|Epithelioid Mesothelioma|Peritoneal Malignant Mesothelioma|Pleural Biphasic Mesothelioma|Pleural Epithelioid Mesothelioma|Pleural Malignant Mesothelioma|Pleural Sarcomatoid Mesothelioma|Recurrent Peritoneal Malignant Mesothelioma|Recurrent Pleural Malignant Mesothelioma|Sarcomatoid Mesothelioma

Estimated Enrollment: 65

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: IRB14-1381|NCI-2015-00348|P30CA014599

Study First Received: March 13, 2015

Last Updated: November 14, 2016

Estimated Primary Completion Date: March 2018

Primary Outcome Measures:

Ability of PD-L1 to predict response|Overall survival (OS)|Progression free survival (PFS)|Disease control rate (CR + PR + SD)

Sponsors and Collaborators:

University of Chicago|National Cancer Institute (NCI)

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02399371

Was this article helpful?
Views: 51